Single-use Bioreactors Market Size & Growth Forecast 2026–2035, By Segments (Usage Type, End-use, Product Scope, Type, Molecule Type, Application, Type of Cell), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape
Market Size and Growoth Outlook
Single-use Bioreactors Market size was worth USD 4.99 Billion in 2025 and is poised to grow at a 17% CAGR between 2026 and 2035, reaching USD 23.99 Billion by 2035. The industry revenue for 2026 is assessed at USD 5.75 billion.
Get more details on this report
Request Free Sample ReportSingle-use Bioreactors Market Intelligence Snapshot
Regional Market Dynamics
- North America held a 36.29% share in 2025, driven by its strong biopharmaceutical manufacturing base, mature outsourcing ecosystem, and widespread adoption of flexible biologics production systems.
- Asia Pacific is projected to expand at a 19.04% CAGR as biologics manufacturing capacity grows and facilities increasingly adopt disposable systems for faster setup, scalability, and cost-efficient production.
Segment Momentum
- Lab-scale Production held a 37.76% share in 2025 because it supports early-stage research, pilot studies, and rapid process development through flexible systems with reduced cleaning and changeover requirements.
- Pharmaceutical & Biopharmaceutical Companies are the fastest-growing end users as they expand flexible manufacturing capacity to accelerate development timelines and improve adaptability across multiple biologic production programs.
Market Expansion Drivers
- Flexibility and contamination reduction accelerating biopharmaceutical production adoption.
- Lower operational costs and faster turnaround versus stainless steel systems.
- Expanding biologics pipeline and scaling of CMO/CDMO manufacturing capacity.
Leading Market Participants
Global Market Forecast Snapshot
Market Outlook
Major companies in the single-use bioreactors market include Sartorius AG (Germany), Thermo Fisher Scientific Inc. (United States), Merck KGaA (Germany), Danaher Corporation (United States), Lonza Group AG (Switzerland), Getinge AB (Sweden), Eppendorf SE (Germany), PBS Biotech, Inc. (United States), Celltainer Biotech B.V. (Netherlands), Cellexus International Ltd. (United Kingdom).Regional and Segment Outlook
North AmericaMarket Growth Drivers and Industry Trends
Biopharmaceutical manufacturers increasingly favor modular production setups that can be deployed quickly, reconfigured between products, and operated with lower cross-batch contamination risk, which is increasing demand for the single-use bioreactors market. Single-use systems remove much of the cleaning validation and sterilization burden associated with fixed stainless steel infrastructure, making them especially attractive for facilities handling multiple biologics, clinical-stage programs, or smaller commercial batches. In practice, this flexibility supports faster product changeovers and shortens facility readiness timelines, while the reduced contamination exposure strengthens confidence in batch integrity and reinforces market adoption among firms prioritizing speed, product segregation, and manufacturing reliability.
Lower operational costs and faster turnaround versus stainless steel systems
Cost discipline and production agility are closely linked in bioprocessing decisions, and both are aiding market expansion for the single-use bioreactors market as manufacturers seek alternatives to capital-intensive stainless steel systems. Disposable bioreactor formats reduce spending tied to cleaning utilities, steam generation, water-for-injection consumption, and maintenance of permanent vessels, while also limiting downtime between batches. That operating model influences procurement and capacity planning in practice: companies can bring lines online faster, improve asset utilization, and respond more efficiently to fluctuating production schedules, which is increasing market adoption among both established biologics producers and emerging biotech firms.
Expanding biologics pipeline and scaling of CMO/CDMO manufacturing capacity
A broader biologics development pipeline is translating into more outsourced manufacturing activity, and that dynamic is strengthening market development for the single-use bioreactors market. CMOs and CDMOs need equipment platforms that can support diverse molecules, variable batch sizes, and overlapping client timelines without locking capacity into inflexible fixed systems. Single-use bioreactors fit this model by enabling rapid suite turnover and easier scale-up from process development to commercial production, which aligns with how outsourced manufacturers build capacity around responsiveness and multi-client utilization. As biologics sponsors rely more heavily on external partners to advance programs and expand output, investment in disposable bioprocessing infrastructure is contributing to market size growth.
| Growth Driver | Impact on CAGR | Regulatory Influence | Geographic Relevance | Adoption Rate | Impact Timeline |
|---|---|---|---|---|---|
| Flexibility and contamination reduction accelerating biopharmaceutical production adoption | 2.50% | High | North America, Europe, Asia Pacific | High | Near Term |
| Lower operational costs and faster turnaround versus stainless steel systems | 2.10% | High | North America, Europe | High | Near Term |
| Expanding biologics pipeline and scaling of CMO/CDMO manufacturing capacity | 1.90% | High | North America, Asia Pacific, Europe | Medium | Mid Term |
Unlock insights tailored to your business with our bespoke market research solutions.
Click to get your customized report now.
Regional Demand Dynamics
North America held a 36.29% share of the single-use bioreactors market in 2025, bolstered by the region’s established biopharmaceutical manufacturing base and broad use of flexible production systems across commercial and clinical-scale operations. Demand remains concentrated in settings where manufacturers need faster batch changeovers, lower cleaning validation burdens, and scalable capacity for biologics production, all of which favor single-use deployment. The region’s position is further strengthened by the presence of major industry participants, mature outsourcing networks, and sustained investment in process optimization, which keeps adoption embedded in everyday manufacturing decisions.
Asia Pacific is projected to expand at a 19.04% CAGR over the forecast period, with the single-use bioreactors market gaining momentum as biopharmaceutical capacity builds out across both domestic production and contract manufacturing environments. Growth is being impelled by increasing installation of modern biologics facilities that prefer disposable systems for quicker setup, lower upfront infrastructure requirements, and easier adaptation to changing production volumes. As manufacturers in the region scale development and manufacturing capabilities, adoption is accelerating in practical use cases where speed, flexibility, and cost control are central to facility planning.
| Parameter | North America | Asia Pacific | Europe | Latin America | MEA |
|---|---|---|---|---|---|
| Innovation Hub i Scale Nascent Developing Advanced | |||||
| Cost-Sensitive Region i Scale Low Medium High | |||||
| Regulatory Environment i Scale Restrictive Neutral Supportive | |||||
| Demand Drivers i Scale Weak Moderate Strong | |||||
| Development Stage i Scale Emerging Developing Developed | |||||
| Adoption Rate i Scale Low Medium High | |||||
| New Entrants / Startups i Scale Sparse Moderate Dense | |||||
| Macro Indicators i Scale Weak Stable Strong |
Key Country Insights
Germany 🇩🇪
Advanced Manufacturing IntegrationGermany integrates single-use bioreactors into highly automated biopharmaceutical production environments. Manufacturers in Germany focus on efficient process validation, equipment compatibility, and sustainable production practices while supporting diverse biologics manufacturing requirements.
France 🇫🇷
Flexible Production StrategyFrance incorporates single-use bioreactors to support clinical manufacturing and specialized biologics production with greater operational flexibility. Organizations in France prioritize efficient facility utilization, faster changeovers, and reliable production processes for innovative therapies.
Italy 🇮🇹
Specialized Biomanufacturing SupportItaly applies single-use bioreactors across research organizations and pharmaceutical manufacturers seeking adaptable production capabilities. Companies in Italy emphasize cost-efficient scale-up, process consistency, and technology upgrades that support expanding biologics development activities.
Japan 🇯🇵
Quality-Focused BioprocessingJapan adopts single-use bioreactors to improve manufacturing flexibility while maintaining stringent quality standards for biologics production. Organizations in Japan emphasize reliable process control, regulatory compliance, and consistent product quality across development and manufacturing stages.
South Korea 🇰🇷
Biologics Capacity DevelopmentSouth Korea continues strengthening biopharmaceutical manufacturing through broader adoption of single-use bioreactor technologies. Companies in South Korea invest in modern production facilities capable of supporting contract manufacturing, process efficiency, and rapid product transitions.
United States 🇺🇸
Bioprocess Expansion CenterThe U.S. continues investing in flexible biomanufacturing capacity where single-use bioreactors support rapid process development and commercial production. Companies across the U.S. prioritize scalable manufacturing platforms, automation, and contamination risk reduction for biologics production.
Segment Leadership and Growth Trends
Single-use Bioreactors Market Share (%), Usage Type, 2025
Go beyond the chart, access full insights & data tables
Request Free Sample ReportLab-scale Production held the leading position in the single-use bioreactors market in 2025, accounting for a 37.76% share. Its leadership is underpinned by the high volume of early-stage research, process development, and pilot experimentation that relies on flexible bioreactor setups with lower changeover burden. In the single-use bioreactors market, lab-scale systems fit well with rapid testing cycles and small-batch workflows, making them a practical choice for organizations that need speed, containment efficiency, and reduced cleaning requirements during development activities.
Large-scale Production is the fastest-growing segment in the single-use bioreactors market as manufacturers increasingly extend disposable technologies into commercial and late-stage production environments. Growth is being backed by the need to expand output without the long installation timelines and operational rigidity associated with traditional stainless-steel systems. Compared with smaller-scale use cases, large-scale production is gaining momentum because it directly addresses evolving manufacturing requirements for scalable capacity, faster facility readiness, and more adaptable batch production.
End-use Segment Analysis: CROs & CMOs (Largest Segment) vs Pharmaceutical & Biopharmaceutical Companies (Fastest-Growing Segment)
In 2025, CROs & CMOs represented the largest end-use segment in the single-use bioreactors market, with a 40.97% share. Their leadership reflects the outsourced manufacturing model increasingly used across bioprocessing, where clients depend on external partners for development and production flexibility. The single-use bioreactors market benefits from this model because CROs and CMOs must manage varied client programs, smaller batch runs, and frequent product changeovers, all of which align well with disposable bioreactor platforms.
Pharmaceutical & Biopharmaceutical Companies are emerging as the fastest-growing end-use segment in the single-use bioreactors market due to rising internal adoption of flexible manufacturing infrastructure. Growth is being driven by the need to shorten development-to-production timelines while maintaining operational adaptability across different biologic programs. Relative to outsourced settings, direct adoption by pharmaceutical and biopharmaceutical companies is gaining pace as these firms increasingly build or upgrade facilities around single-use systems to support faster process transitions and more responsive production planning.
| Segment | Sub-Segment | Largest Segment | Fastest Growing |
|---|---|---|---|
| Usage Type | Lab-scale Production, Pilot-scale Production, Large-scale Production | Lab-scale Production | Large-scale Production |
| End-use | Pharmaceutical & Biopharmaceutical Companies, CROs & CMOs, Academic & Research Institutes | CROs & CMOs | Pharmaceutical & Biopharmaceutical Companies |
| Product Scope | Single-use Bioreactor Systems, Single-use Media Bags, Single-use Filtration Assemblies, Others | Single-use Bioreactor Systems | Single-use Bioreactor Systems |
| Type | Stirred-tank SUBs, Wave-induced SUBs, Bubble-column SUBs, Others | Stirred-tank SUBs | Stirred-tank SUBs |
| Molecule Type | Monoclonal Antibodies, Vaccines, Gene Modified Cells, Stem Cells, Others | Vaccines | Gene Modified Cells |
| Application | Research and Development (R&D)or Process Development, Bioproduction | Bioproduction | Bioproduction |
| Type of Cell | Mammalian Cells, Bacterial Cells, Yeast Cells, Others | Mammalian Cells | Mammalian Cells |
Competitive Landscape and Market Positioning
1. Sartorius AG (Germany)
2. Thermo Fisher Scientific Inc. (United States)
3. Merck KGaA (Germany)
4. Danaher Corporation (United States)
5. Lonza Group AG (Switzerland)
6. Getinge AB (Sweden)
7. Eppendorf SE (Germany)
8. PBS Biotech Inc. (United States)
9. Celltainer Biotech B.V. (Netherlands)
10. Cellexus International Ltd. (United Kingdom)
The single-use bioreactors market is growing rapidly due to increasing demand for flexible biomanufacturing solutions. In the single-use bioreactors market, advancements in disposable system design are improving production scalability. Enhanced process control technologies are also supporting biopharmaceutical innovation.
| Company | Market Share | Company Revenue | Revenue CAGR (%) | Product Portfolio | Geographic Presence | Innovation / R&D Focus | Strategic Developments |
|---|---|---|---|---|---|---|---|
| No companies available. | |||||||
Industry Development/News
| Company Name | Date | Key Development |
|---|---|---|
| AGC Biologics | Apr-25 | AGC Biologics integrated two 5,000L Thermo Scientific DynaDrive single-use bioreactors into its Yokohama facility. This investment enhances the site's capability for large-scale mammalian-based biologic production, establishing a sophisticated infrastructure in Japan to meet the growing demand for flexible, high-capacity CDMO manufacturing services. |
| WuXi Biologics | Apr-25 | WuXi Biologics successfully completed the first commercial Process Performance Qualification (PPQ) campaign at its MFG20 facility in Hangzhou. The project utilized a second drug substance line equipped with three 5,000L single-use bioreactors, validating the facility's readiness for large-scale commercial biologics manufacturing and operational scalability. |
| Fujifilm Biotechnologies | Nov-24 | Fujifilm Biotechnologies completed a £400 million expansion of its Teesside facility, adding 19,000L of single-use bioreactor capacity alongside a new innovation center. This investment significantly bolsters the company’s global CDMO antibody production capabilities and process development infrastructure to support increasing biopharmaceutical manufacturing volume requirements. |
| Bora Group | Nov-24 | Bora Group acquired MacroGenics’ CDMO operations for up to $127.5 million, securing a Maryland-based drug-substance facility. The acquisition integrates advanced single-use bioprocessing capabilities into Bora’s biologics platform, expanding its total capacity for late-stage development and commercial-scale manufacturing of complex biologic drug products. |
| WuXi Biologics | Oct-24 | WuXi Biologics expanded its manufacturing footprint by installing three 5,000L single-use bioreactors, effectively increasing total site capacity from 8,000L to 23,000L. This capacity upgrade enhances GMP production throughput and cost-efficiency, reinforcing the industry-wide shift toward large-scale single-use technologies for commercial antibody manufacturing operations. |
| Syngene | Oct-24 | Syngene initiated an expansion of its biomanufacturing infrastructure in India, with a new facility projected to triple its current production capacity. The investment enhances the company’s CDMO service offerings, specifically targeting the demand for large-scale, single-use bioreactor-based production processes for pharmaceutical and biopharmaceutical clients. |
| Thermo Fisher Scientific | Oct-24 | Thermo Fisher Scientific partnered with the Telangana government to establish a 10,000 sq. ft. Bioprocess Design Center in India, with operations commencing in 2025. The center will focus on advancing biotherapeutic development workflows, specifically enhancing technical capabilities in single-use bioreactor design and regional bioprocessing innovation. |
| MicroDigital | Oct-24 | MicroDigital launched a new line of single-use bioreactors in the United States, officially entering the commercial bioprocessing equipment supply market. The technology provides manufacturers with flexible, scalable solutions for biologics production, reflecting the increasing availability and adoption of disposable bioprocessing systems in the North American pharmaceutical sector. |
| Biosphere | Oct-24 | Biosphere secured $8.8 million in seed funding to advance its UV-sterilized, single-use bioreactor platform. The investment is targeted at scaling technology designed to lower biomanufacturing costs and improve process efficiency, representing a strategic effort to introduce novel sterilization methods into standard single-use production workflows. |
| Aragen | Dec-24 | Aragen demonstrated accelerated commercial GMP scale-up capabilities by transferring a monoclonal antibody program from California to Bengaluru in nine months. The successful execution utilized single-use bioreactor production workflows, highlighting the company’s improved tech transfer speed and CDMO execution proficiency for high-risk therapeutic manufacturing. |
Explore This Report
Click a section of the wheel — or its numbered marker — to preview the custom segmentation, custom table of contents, or related reports available for this market.
Single-use Bioreactors Market — Custom Segments
| Segment | Sub-Segment |
|---|---|
| No segment data available. | |
Single-use Bioreactors Market — report.custom
| Custom Chapter | Custom Details | ||
|---|---|---|---|
| No custom TOC data available. | |||
Need a different cut of the data?
Request Custom ResearchWhat is the market size of single-use bioreactors?
How is the single-use bioreactors industry projected to perform over the next decade?
How is the shift toward flexible and contamination-controlled manufacturing influencing adoption in the single-use bioreactors market?
Why is expansion of outsourced biomanufacturing capacity accelerating growth in the single-use bioreactors market?
Why is Lab-scale Production the largest usage type in the single-use bioreactors market?
Why are Pharmaceutical & Biopharmaceutical Companies the fastest-growing end-use segment in the single-use bioreactors market?
What factors make North America the leading region in the single-use bioreactors market?
Why is Asia Pacific experiencing the fastest growth in the single-use bioreactors market?
Which organizations are considered leaders in the single-use bioreactors landscape?
Our Clients
"The reports offered a comprehensive view of the Food and Beverage landscape, covering market trends, consumer behavior, and competitive dynamics."
"Our experience in acquiring market research reports has been outstanding — the depth of analysis and actionable insights have proven invaluable."
"Fundamental Business Insights demonstrated a keen understanding of our business needs, delivering reports tailored to our specific objectives."
Our Research Team & Methodology
Every Fundamental Business Insights report is built by a dedicated vertical research team, validated through a structured primary-and-secondary methodology, and reviewed for accuracy before it reaches you.
Research Team Overview
Prepared by the Healthcare & Medical Devices Research Team
Delivery
Published
Demand
Available
Support
Trust & Compliance
Research Domains
10 coverage areasResearch Intelligence
| Source Category | Research Sources | Purpose |
|---|---|---|
| Government Publications | Government agencies, statistical departments, regulatory bodies | Industry statistics, regulatory insights, and policy analysis |
| Company Disclosures | Annual reports, investor presentations, financial filings | Company performance, business strategy, and market positioning |
| Trade Associations | Industry associations and professional organizations | Industry developments, standards, and market perspectives |
| Technical Literature | Research papers, technical publications, academic journals | Technology developments and technical validation |
| Patent Analysis | Patent databases and intellectual property publications | Innovation trends, technology activity, and competitive research |
| Industry Databases | Established research databases and market intelligence resources | Market benchmarking, historical data, and industry analysis |
Research Workflow & Quality Assurance
Data Collection
Verified information gathered through primary and secondary research.
Data Triangulation
Cross-validation using multiple independent data sources.
Forecast Modelling
Market estimates developed using historical trends and analytical models.
Analyst Validation
Findings reviewed by domain experts for accuracy and consistency.
Editorial & Quality Review
Final editorial, quality, and compliance checks before publication.
Final Publication
Released after successful completion of the internal review process.
Report Coverage
📊 Market Assessment
- Market Size & Forecast
- Market Segmentation
- Regional Analysis
- Growth Drivers & Challenges
- Market Dynamics
🏢 Competitive Intelligence
- Competitive Landscape
- Company Profiles
- Competitive Benchmarking
- Mergers & Acquisitions
- Market Share Analysis or Key Company Strategies
🔍 Strategic Analysis
- Value Chain Analysis
- Porter's Five Forces
- PESTLE Analysis
- Pricing Trends
- Supply-Demand Analysis
🚀 Future Outlook
- Technology Landscape
- Regulatory Landscape
- Investment & Funding Landscape
- Emerging Opportunities
- Future Market Outlook
Have a question about this report or need a custom scope?
Request Customization